Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein.
Hypoxia-inducible transcription factor 1 (HIF-1) and HIF-2alpha regulate the expression of an expansive array of genes associated with cellular responses to hypoxia. Although HIF-regulated genes mediate crucial beneficial short-term biological adaptations, we hypothesized that chronic activation of the HIF pathway in cardiac muscle, as occurs in advanced ischemic heart disease, is detrimental. We generated mice with cardiac myocyte-specific deletion of the von Hippel-Lindau protein (VHL), an essential component of an E3 ubiquitin ligase responsible for suppressing HIF levels during normoxia. These mice were born at expected frequency and thrived until after 3 months postbirth, when they developed severe progressive heart failure and premature death. VHL-null hearts developed lipid accumulation, myofibril rarefaction, altered nuclear morphology, myocyte loss, and fibrosis, features seen for various forms of human heart failure. Further, nearly 50% of VHL(-/-) hearts developed malignant cardiac tumors with features of rhabdomyosarcoma and the capacity to metastasize. As compelling evidence for the mechanistic contribution of HIF-1alpha, the concomitant deletion of VHL and HIF-1alpha in the heart prevented this phenotype and restored normal longevity. These findings strongly suggest that chronic activation of the HIF pathway in ischemic hearts is maladaptive and contributes to cardiac degeneration and progression to heart failure.
Lei
Li
L
Cardiovascular Gene Therapy Program, Department of Medicine, Yale University School of Medicine, New Haven, CT 06510, USA.
Mason
Steve
S
Liu
Dinggang
D
Huang
Yan
Y
Marks
Carolyn
C
Hickey
Reed
R
Jovin
Ion S
IS
Pypaert
Marc
M
Johnson
Randall S
RS
Giordano
Frank J
FJ
D000818:Animals; D002196:Capillaries / Q000254:growth & development; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D066246:ErbB Receptors / Q000378:metabolism; D017353:Gene Deletion; D018014:Gene Transfer Techniques; D006333:Heart Failure / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D006338:Heart Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D000860:Hypoxia / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics* / Q000378:metabolism; D050356:Lipid Metabolism / Q000235:genetics; D008055:Lipids / Q000032:analysis; D051379:Mice; D018345:Mice, Knockout; D009206:Myocardium / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology*; D018919:Neovascularization, Physiologic / Q000235:genetics; D010766:Phosphorylation; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics*; D018631:ras Proteins / Q000378:metabolism
C497443:Hif1a protein, mouse; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D008055:Lipids; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D066246:ErbB Receptors; D019859:Proto-Oncogene Proteins c-met; D018631:ras Proteins; C494469:VHL protein, mouse